nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Cyclosporine—focal segmental glomerulosclerosis	0.0774	0.469	CbGbCtD
Dasatinib—CYP3A5—Cyclosporine—focal segmental glomerulosclerosis	0.0429	0.26	CbGbCtD
Dasatinib—ABCB1—Cyclosporine—focal segmental glomerulosclerosis	0.0279	0.169	CbGbCtD
Dasatinib—CYP3A4—Cyclosporine—focal segmental glomerulosclerosis	0.0167	0.101	CbGbCtD
Dasatinib—Posterior reversible encephalopathy syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.013	0.0639	CcSEcCtD
Dasatinib—Acute respiratory distress syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00815	0.0402	CcSEcCtD
Dasatinib—RIPK2—endothelium—focal segmental glomerulosclerosis	0.00813	0.0448	CbGeAlD
Dasatinib—EPHB1—kidney—focal segmental glomerulosclerosis	0.007	0.0385	CbGeAlD
Dasatinib—EPHB4—endothelium—focal segmental glomerulosclerosis	0.00687	0.0378	CbGeAlD
Dasatinib—Eye swelling—Cyclosporine—focal segmental glomerulosclerosis	0.00652	0.0322	CcSEcCtD
Dasatinib—Pigmentation disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00637	0.0314	CcSEcCtD
Dasatinib—Uterine haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00609	0.03	CcSEcCtD
Dasatinib—SRC—endothelium—focal segmental glomerulosclerosis	0.00584	0.0322	CbGeAlD
Dasatinib—SRMS—kidney—focal segmental glomerulosclerosis	0.00562	0.031	CbGeAlD
Dasatinib—SIK3—nephron tubule—focal segmental glomerulosclerosis	0.00533	0.0294	CbGeAlD
Dasatinib—STAT5B—kidney—focal segmental glomerulosclerosis	0.00521	0.0287	CbGeAlD
Dasatinib—KIT—endothelium—focal segmental glomerulosclerosis	0.00476	0.0262	CbGeAlD
Dasatinib—SIK3—cortex of kidney—focal segmental glomerulosclerosis	0.00456	0.0251	CbGeAlD
Dasatinib—Swelling face—Cyclosporine—focal segmental glomerulosclerosis	0.00447	0.022	CcSEcCtD
Dasatinib—TESK1—nephron tubule—focal segmental glomerulosclerosis	0.00438	0.0241	CbGeAlD
Dasatinib—Myositis—Cyclosporine—focal segmental glomerulosclerosis	0.00434	0.0214	CcSEcCtD
Dasatinib—CSK—nephron tubule—focal segmental glomerulosclerosis	0.00401	0.0221	CbGeAlD
Dasatinib—TESK1—cortex of kidney—focal segmental glomerulosclerosis	0.00375	0.0206	CbGeAlD
Dasatinib—Gingival bleeding—Cyclosporine—focal segmental glomerulosclerosis	0.00375	0.0185	CcSEcCtD
Dasatinib—RIPK2—nephron tubule—focal segmental glomerulosclerosis	0.00372	0.0205	CbGeAlD
Dasatinib—STK36—cortex of kidney—focal segmental glomerulosclerosis	0.00369	0.0203	CbGeAlD
Dasatinib—SIK1—nephron tubule—focal segmental glomerulosclerosis	0.00364	0.02	CbGeAlD
Dasatinib—LIMK2—cortex of kidney—focal segmental glomerulosclerosis	0.00357	0.0196	CbGeAlD
Dasatinib—ERBB3—nephron tubule—focal segmental glomerulosclerosis	0.00357	0.0196	CbGeAlD
Dasatinib—MAP3K2—nephron tubule—focal segmental glomerulosclerosis	0.00353	0.0194	CbGeAlD
Dasatinib—CSK—kidney—focal segmental glomerulosclerosis	0.00353	0.0194	CbGeAlD
Dasatinib—Polyp—Cyclosporine—focal segmental glomerulosclerosis	0.0035	0.0172	CcSEcCtD
Dasatinib—Optic neuritis—Cyclosporine—focal segmental glomerulosclerosis	0.00346	0.017	CcSEcCtD
Dasatinib—CSK—cortex of kidney—focal segmental glomerulosclerosis	0.00343	0.0189	CbGeAlD
Dasatinib—Nail disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00328	0.0162	CcSEcCtD
Dasatinib—SIK1—kidney—focal segmental glomerulosclerosis	0.0032	0.0176	CbGeAlD
Dasatinib—Cyst—Cyclosporine—focal segmental glomerulosclerosis	0.00318	0.0157	CcSEcCtD
Dasatinib—EPHB4—nephron tubule—focal segmental glomerulosclerosis	0.00315	0.0173	CbGeAlD
Dasatinib—ERBB3—kidney—focal segmental glomerulosclerosis	0.00313	0.0173	CbGeAlD
Dasatinib—SIK1—cortex of kidney—focal segmental glomerulosclerosis	0.00311	0.0171	CbGeAlD
Dasatinib—EPHA2—nephron tubule—focal segmental glomerulosclerosis	0.00309	0.017	CbGeAlD
Dasatinib—FYN—nephron tubule—focal segmental glomerulosclerosis	0.00308	0.017	CbGeAlD
Dasatinib—MAP3K3—nephron tubule—focal segmental glomerulosclerosis	0.00301	0.0166	CbGeAlD
Dasatinib—Thrombosis—Cyclosporine—focal segmental glomerulosclerosis	0.003	0.0148	CcSEcCtD
Dasatinib—Interstitial lung disease—Cyclosporine—focal segmental glomerulosclerosis	0.003	0.0148	CcSEcCtD
Dasatinib—Tongue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00292	0.0144	CcSEcCtD
Dasatinib—MAPK14—kidney—focal segmental glomerulosclerosis	0.00292	0.0161	CbGeAlD
Dasatinib—Cholestasis—Cyclosporine—focal segmental glomerulosclerosis	0.0028	0.0138	CcSEcCtD
Dasatinib—YES1—nephron tubule—focal segmental glomerulosclerosis	0.00278	0.0153	CbGeAlD
Dasatinib—EPHB4—kidney—focal segmental glomerulosclerosis	0.00277	0.0152	CbGeAlD
Dasatinib—JAK2—kidney—focal segmental glomerulosclerosis	0.00275	0.0151	CbGeAlD
Dasatinib—Skin ulcer—Cyclosporine—focal segmental glomerulosclerosis	0.00273	0.0135	CcSEcCtD
Dasatinib—Coagulopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00273	0.0135	CcSEcCtD
Dasatinib—FYN—kidney—focal segmental glomerulosclerosis	0.00271	0.0149	CbGeAlD
Dasatinib—EPHB4—cortex of kidney—focal segmental glomerulosclerosis	0.00269	0.0148	CbGeAlD
Dasatinib—JAK2—cortex of kidney—focal segmental glomerulosclerosis	0.00267	0.0147	CbGeAlD
Dasatinib—FYN—cortex of kidney—focal segmental glomerulosclerosis	0.00264	0.0145	CbGeAlD
Dasatinib—MAP3K3—cortex of kidney—focal segmental glomerulosclerosis	0.00258	0.0142	CbGeAlD
Dasatinib—MAP4K5—cortex of kidney—focal segmental glomerulosclerosis	0.00258	0.0142	CbGeAlD
Dasatinib—Neoplasm malignant—Cyclosporine—focal segmental glomerulosclerosis	0.00249	0.0123	CcSEcCtD
Dasatinib—EPHB6—cortex of kidney—focal segmental glomerulosclerosis	0.00246	0.0136	CbGeAlD
Dasatinib—YES1—kidney—focal segmental glomerulosclerosis	0.00244	0.0135	CbGeAlD
Dasatinib—Cardiovascular disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00242	0.0119	CcSEcCtD
Dasatinib—Rhabdomyolysis—Cyclosporine—focal segmental glomerulosclerosis	0.0024	0.0118	CcSEcCtD
Dasatinib—YES1—cortex of kidney—focal segmental glomerulosclerosis	0.00238	0.0131	CbGeAlD
Dasatinib—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.00237	0.0117	CcSEcCtD
Dasatinib—SRC—kidney—focal segmental glomerulosclerosis	0.00235	0.013	CbGeAlD
Dasatinib—Hyperuricaemia—Cyclosporine—focal segmental glomerulosclerosis	0.00229	0.0113	CcSEcCtD
Dasatinib—Creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00223	0.011	CcSEcCtD
Dasatinib—KIT—nephron tubule—focal segmental glomerulosclerosis	0.00218	0.012	CbGeAlD
Dasatinib—Blood uric acid increased—Cyclosporine—focal segmental glomerulosclerosis	0.00217	0.0107	CcSEcCtD
Dasatinib—MAP2K5—cortex of kidney—focal segmental glomerulosclerosis	0.00211	0.0116	CbGeAlD
Dasatinib—Fluid retention—Cyclosporine—focal segmental glomerulosclerosis	0.00202	0.00995	CcSEcCtD
Dasatinib—Neuropathy—Cyclosporine—focal segmental glomerulosclerosis	0.002	0.00984	CcSEcCtD
Dasatinib—Oesophagitis—Cyclosporine—focal segmental glomerulosclerosis	0.00194	0.00958	CcSEcCtD
Dasatinib—Neoplasm—Cyclosporine—focal segmental glomerulosclerosis	0.00192	0.00948	CcSEcCtD
Dasatinib—KIT—kidney—focal segmental glomerulosclerosis	0.00192	0.0106	CbGeAlD
Dasatinib—Gynaecomastia—Cyclosporine—focal segmental glomerulosclerosis	0.0019	0.00938	CcSEcCtD
Dasatinib—ABL1—nephron tubule—focal segmental glomerulosclerosis	0.0019	0.0105	CbGeAlD
Dasatinib—PDGFRB—kidney—focal segmental glomerulosclerosis	0.00187	0.0103	CbGeAlD
Dasatinib—KIT—cortex of kidney—focal segmental glomerulosclerosis	0.00187	0.0103	CbGeAlD
Dasatinib—Sepsis—Cyclosporine—focal segmental glomerulosclerosis	0.00185	0.0091	CcSEcCtD
Dasatinib—PDGFRB—cortex of kidney—focal segmental glomerulosclerosis	0.00182	0.01	CbGeAlD
Dasatinib—Eczema—Cyclosporine—focal segmental glomerulosclerosis	0.00172	0.00847	CcSEcCtD
Dasatinib—ABL1—kidney—focal segmental glomerulosclerosis	0.00167	0.00919	CbGeAlD
Dasatinib—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00166	0.00821	CcSEcCtD
Dasatinib—Visual disturbance—Cyclosporine—focal segmental glomerulosclerosis	0.00163	0.00803	CcSEcCtD
Dasatinib—ABL1—cortex of kidney—focal segmental glomerulosclerosis	0.00163	0.00895	CbGeAlD
Dasatinib—CYP1B1—nephron tubule—focal segmental glomerulosclerosis	0.00161	0.00886	CbGeAlD
Dasatinib—Cardiac failure—Cyclosporine—focal segmental glomerulosclerosis	0.00158	0.0078	CcSEcCtD
Dasatinib—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.00153	0.00755	CcSEcCtD
Dasatinib—Affect lability—Cyclosporine—focal segmental glomerulosclerosis	0.00152	0.00749	CcSEcCtD
Dasatinib—Blood creatinine increased—Cyclosporine—focal segmental glomerulosclerosis	0.00145	0.00713	CcSEcCtD
Dasatinib—Dry skin—Cyclosporine—focal segmental glomerulosclerosis	0.00141	0.00697	CcSEcCtD
Dasatinib—CYP1B1—kidney—focal segmental glomerulosclerosis	0.00141	0.00778	CbGeAlD
Dasatinib—Breast disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00139	0.00688	CcSEcCtD
Dasatinib—CYP1B1—cortex of kidney—focal segmental glomerulosclerosis	0.00138	0.00758	CbGeAlD
Dasatinib—Gastritis—Cyclosporine—focal segmental glomerulosclerosis	0.00137	0.00673	CcSEcCtD
Dasatinib—Muscular weakness—Cyclosporine—focal segmental glomerulosclerosis	0.00136	0.00671	CcSEcCtD
Dasatinib—Abdominal distension—Cyclosporine—focal segmental glomerulosclerosis	0.00134	0.00662	CcSEcCtD
Dasatinib—Dysphagia—Cyclosporine—focal segmental glomerulosclerosis	0.00133	0.00658	CcSEcCtD
Dasatinib—Bronchospasm—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00647	CcSEcCtD
Dasatinib—Pancreatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00131	0.00645	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00124	0.00611	CcSEcCtD
Dasatinib—Pollakiuria—Cyclosporine—focal segmental glomerulosclerosis	0.00123	0.00608	CcSEcCtD
Dasatinib—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00599	CcSEcCtD
Dasatinib—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00121	0.00595	CcSEcCtD
Dasatinib—ABCG2—nephron tubule—focal segmental glomerulosclerosis	0.0012	0.0066	CbGeAlD
Dasatinib—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.0012	0.0059	CcSEcCtD
Dasatinib—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00586	CcSEcCtD
Dasatinib—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00119	0.00586	CcSEcCtD
Dasatinib—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00578	CcSEcCtD
Dasatinib—Renal failure—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00576	CcSEcCtD
Dasatinib—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00575	CcSEcCtD
Dasatinib—Neuropathy peripheral—Cyclosporine—focal segmental glomerulosclerosis	0.00117	0.00575	CcSEcCtD
Dasatinib—Stomatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.00572	CcSEcCtD
Dasatinib—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00116	0.0057	CcSEcCtD
Dasatinib—Haematuria—Cyclosporine—focal segmental glomerulosclerosis	0.00113	0.00559	CcSEcCtD
Dasatinib—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00555	CcSEcCtD
Dasatinib—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00112	0.00553	CcSEcCtD
Dasatinib—CYP3A5—nephron tubule—focal segmental glomerulosclerosis	0.00111	0.00612	CbGeAlD
Dasatinib—Haemoglobin—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00529	CcSEcCtD
Dasatinib—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00526	CcSEcCtD
Dasatinib—Haemorrhage—Cyclosporine—focal segmental glomerulosclerosis	0.00107	0.00526	CcSEcCtD
Dasatinib—Urinary tract disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.0052	CcSEcCtD
Dasatinib—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00517	CcSEcCtD
Dasatinib—Urethral disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00105	0.00516	CcSEcCtD
Dasatinib—Visual impairment—Cyclosporine—focal segmental glomerulosclerosis	0.00103	0.00507	CcSEcCtD
Dasatinib—CYP1A1—kidney—focal segmental glomerulosclerosis	0.000999	0.0055	CbGeAlD
Dasatinib—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.000996	0.00491	CcSEcCtD
Dasatinib—Flushing—Cyclosporine—focal segmental glomerulosclerosis	0.000991	0.00489	CcSEcCtD
Dasatinib—CYP3A5—kidney—focal segmental glomerulosclerosis	0.000977	0.00538	CbGeAlD
Dasatinib—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.000969	0.00478	CcSEcCtD
Dasatinib—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000962	0.00474	CcSEcCtD
Dasatinib—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.000958	0.00472	CcSEcCtD
Dasatinib—Arrhythmia—Cyclosporine—focal segmental glomerulosclerosis	0.000954	0.0047	CcSEcCtD
Dasatinib—CYP3A5—cortex of kidney—focal segmental glomerulosclerosis	0.000951	0.00524	CbGeAlD
Dasatinib—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.000944	0.00465	CcSEcCtD
Dasatinib—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000935	0.00461	CcSEcCtD
Dasatinib—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00093	0.00458	CcSEcCtD
Dasatinib—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00091	0.00449	CcSEcCtD
Dasatinib—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.000894	0.00441	CcSEcCtD
Dasatinib—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.000876	0.00432	CcSEcCtD
Dasatinib—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.000871	0.00429	CcSEcCtD
Dasatinib—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000862	0.00425	CcSEcCtD
Dasatinib—Anaemia—Cyclosporine—focal segmental glomerulosclerosis	0.000859	0.00424	CcSEcCtD
Dasatinib—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.000838	0.00413	CcSEcCtD
Dasatinib—Vertigo—Cyclosporine—focal segmental glomerulosclerosis	0.000835	0.00412	CcSEcCtD
Dasatinib—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.000811	0.004	CcSEcCtD
Dasatinib—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.000805	0.00397	CcSEcCtD
Dasatinib—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.000803	0.00396	CcSEcCtD
Dasatinib—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.000791	0.0039	CcSEcCtD
Dasatinib—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.000791	0.0039	CcSEcCtD
Dasatinib—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.000791	0.0039	CcSEcCtD
Dasatinib—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.000789	0.00389	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.000786	0.00387	CcSEcCtD
Dasatinib—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000782	0.00385	CcSEcCtD
Dasatinib—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.000765	0.00377	CcSEcCtD
Dasatinib—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.000759	0.00374	CcSEcCtD
Dasatinib—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.000754	0.00372	CcSEcCtD
Dasatinib—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000744	0.00367	CcSEcCtD
Dasatinib—Thrombocytopenia—Cyclosporine—focal segmental glomerulosclerosis	0.000743	0.00366	CcSEcCtD
Dasatinib—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000737	0.00363	CcSEcCtD
Dasatinib—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.000733	0.00362	CcSEcCtD
Dasatinib—CYP3A4—kidney—focal segmental glomerulosclerosis	0.000733	0.00404	CbGeAlD
Dasatinib—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.000723	0.00356	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.000691	0.00341	CcSEcCtD
Dasatinib—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.000686	0.00338	CcSEcCtD
Dasatinib—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.000676	0.00333	CcSEcCtD
Dasatinib—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.000674	0.00332	CcSEcCtD
Dasatinib—Dyspepsia—Cyclosporine—focal segmental glomerulosclerosis	0.000668	0.00329	CcSEcCtD
Dasatinib—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.000659	0.00325	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.000655	0.00323	CcSEcCtD
Dasatinib—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.000654	0.00322	CcSEcCtD
Dasatinib—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.000649	0.0032	CcSEcCtD
Dasatinib—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.000649	0.0032	CcSEcCtD
Dasatinib—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.000625	0.00308	CcSEcCtD
Dasatinib—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00062	0.00306	CcSEcCtD
Dasatinib—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.000603	0.00297	CcSEcCtD
Dasatinib—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.0006	0.00296	CcSEcCtD
Dasatinib—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.0006	0.00296	CcSEcCtD
Dasatinib—ABCB1—nephron tubule—focal segmental glomerulosclerosis	0.000591	0.00325	CbGeAlD
Dasatinib—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.000559	0.00276	CcSEcCtD
Dasatinib—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.000544	0.00268	CcSEcCtD
Dasatinib—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.000537	0.00265	CcSEcCtD
Dasatinib—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.000519	0.00256	CcSEcCtD
Dasatinib—ABCB1—kidney—focal segmental glomerulosclerosis	0.000519	0.00286	CbGeAlD
Dasatinib—ABCB1—cortex of kidney—focal segmental glomerulosclerosis	0.000505	0.00278	CbGeAlD
Dasatinib—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.000502	0.00247	CcSEcCtD
Dasatinib—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.000482	0.00238	CcSEcCtD
Dasatinib—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.000478	0.00236	CcSEcCtD
Dasatinib—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.000478	0.00236	CcSEcCtD
Dasatinib—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.000475	0.00234	CcSEcCtD
Dasatinib—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.000451	0.00222	CcSEcCtD
Dasatinib—SRC—Signaling Pathways—COL4A3—focal segmental glomerulosclerosis	2.23e-05	4.94e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—CD40LG—focal segmental glomerulosclerosis	2.23e-05	4.94e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.22e-05	4.93e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.21e-05	4.9e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—LIPC—focal segmental glomerulosclerosis	2.21e-05	4.9e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—CD40LG—focal segmental glomerulosclerosis	2.2e-05	4.88e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—MMP9—focal segmental glomerulosclerosis	2.19e-05	4.85e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	2.18e-05	4.84e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—LPL—focal segmental glomerulosclerosis	2.17e-05	4.81e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	2.17e-05	4.81e-05	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—ALB—focal segmental glomerulosclerosis	2.17e-05	4.81e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.15e-05	4.77e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—LIPC—focal segmental glomerulosclerosis	2.14e-05	4.75e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.14e-05	4.75e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.14e-05	4.75e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	2.14e-05	4.74e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—CTGF—focal segmental glomerulosclerosis	2.14e-05	4.74e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.13e-05	4.73e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.13e-05	4.72e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—CD40LG—focal segmental glomerulosclerosis	2.12e-05	4.7e-05	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AGT—focal segmental glomerulosclerosis	2.12e-05	4.7e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.12e-05	4.7e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	2.11e-05	4.69e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	2.1e-05	4.67e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	2.1e-05	4.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—CD40LG—focal segmental glomerulosclerosis	2.09e-05	4.64e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP2—focal segmental glomerulosclerosis	2.07e-05	4.6e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—LPL—focal segmental glomerulosclerosis	2.07e-05	4.59e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	2.07e-05	4.58e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	2.05e-05	4.56e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	2.05e-05	4.54e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.04e-05	4.52e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—SERPINE1—focal segmental glomerulosclerosis	2.04e-05	4.52e-05	CbGpPWpGaD
Dasatinib—CSK—Disease—TGFB1—focal segmental glomerulosclerosis	2.02e-05	4.48e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MMP9—focal segmental glomerulosclerosis	2.01e-05	4.46e-05	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	2e-05	4.45e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—SERPINE1—focal segmental glomerulosclerosis	2e-05	4.43e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—LPL—focal segmental glomerulosclerosis	1.99e-05	4.43e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—ALB—focal segmental glomerulosclerosis	1.99e-05	4.42e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD79A—focal segmental glomerulosclerosis	1.99e-05	4.42e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.97e-05	4.37e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.96e-05	4.35e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.96e-05	4.34e-05	CbGpPWpGaD
Dasatinib—STAT5B—Disease—TGFB1—focal segmental glomerulosclerosis	1.95e-05	4.33e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—CTGF—focal segmental glomerulosclerosis	1.94e-05	4.31e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.94e-05	4.31e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.93e-05	4.27e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.92e-05	4.27e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AGT—focal segmental glomerulosclerosis	1.92e-05	4.27e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.9e-05	4.22e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—LPL—focal segmental glomerulosclerosis	1.9e-05	4.21e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NOS2—focal segmental glomerulosclerosis	1.9e-05	4.21e-05	CbGpPWpGaD
Dasatinib—ABCG2—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.89e-05	4.19e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.89e-05	4.18e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—focal segmental glomerulosclerosis	1.88e-05	4.18e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.86e-05	4.12e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.85e-05	4.11e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.85e-05	4.1e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.84e-05	4.08e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—CD40LG—focal segmental glomerulosclerosis	1.83e-05	4.07e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.8e-05	4e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NOS2—focal segmental glomerulosclerosis	1.79e-05	3.98e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.79e-05	3.97e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.79e-05	3.97e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.78e-05	3.94e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.77e-05	3.93e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.76e-05	3.92e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.76e-05	3.91e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.76e-05	3.91e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.75e-05	3.89e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.75e-05	3.89e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.74e-05	3.87e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.74e-05	3.86e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.73e-05	3.84e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.72e-05	3.83e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.71e-05	3.8e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.71e-05	3.8e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.71e-05	3.8e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.7e-05	3.77e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.7e-05	3.77e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.68e-05	3.73e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—LPL—focal segmental glomerulosclerosis	1.66e-05	3.69e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.66e-05	3.68e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.66e-05	3.68e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.66e-05	3.68e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.65e-05	3.66e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TRPC6—focal segmental glomerulosclerosis	1.64e-05	3.63e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.63e-05	3.63e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.63e-05	3.61e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGTR2—focal segmental glomerulosclerosis	1.63e-05	3.61e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—focal segmental glomerulosclerosis	1.63e-05	3.61e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.63e-05	3.61e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CD40LG—focal segmental glomerulosclerosis	1.62e-05	3.6e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.62e-05	3.59e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NOS2—focal segmental glomerulosclerosis	1.62e-05	3.59e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.61e-05	3.58e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.61e-05	3.57e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.61e-05	3.57e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—SERPINE1—focal segmental glomerulosclerosis	1.6e-05	3.54e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—LIPC—focal segmental glomerulosclerosis	1.58e-05	3.51e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MMP9—focal segmental glomerulosclerosis	1.56e-05	3.46e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NOS2—focal segmental glomerulosclerosis	1.56e-05	3.46e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—TGFB1—focal segmental glomerulosclerosis	1.55e-05	3.43e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.55e-05	3.43e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.52e-05	3.38e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—SERPINE1—focal segmental glomerulosclerosis	1.51e-05	3.35e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.5e-05	3.34e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.49e-05	3.32e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.49e-05	3.31e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NOS2—focal segmental glomerulosclerosis	1.48e-05	3.29e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—LPL—focal segmental glomerulosclerosis	1.48e-05	3.29e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.48e-05	3.28e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—LPL—focal segmental glomerulosclerosis	1.47e-05	3.26e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.46e-05	3.24e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.45e-05	3.23e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.45e-05	3.22e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.44e-05	3.19e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.43e-05	3.16e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.42e-05	3.16e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.42e-05	3.15e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.41e-05	3.14e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.41e-05	3.13e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.4e-05	3.1e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CTGF—focal segmental glomerulosclerosis	1.39e-05	3.09e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.39e-05	3.08e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.38e-05	3.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.37e-05	3.05e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—GNAQ—focal segmental glomerulosclerosis	1.37e-05	3.04e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.37e-05	3.04e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.37e-05	3.04e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—SERPINE1—focal segmental glomerulosclerosis	1.36e-05	3.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—SERPINE1—focal segmental glomerulosclerosis	1.36e-05	3.02e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—LPL—focal segmental glomerulosclerosis	1.35e-05	2.99e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.34e-05	2.98e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	1.34e-05	2.98e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.34e-05	2.98e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.34e-05	2.98e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.33e-05	2.95e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.32e-05	2.94e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.32e-05	2.92e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—SERPINE1—focal segmental glomerulosclerosis	1.31e-05	2.91e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—LPL—focal segmental glomerulosclerosis	1.31e-05	2.9e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NOS2—focal segmental glomerulosclerosis	1.3e-05	2.88e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—TGFB1—focal segmental glomerulosclerosis	1.29e-05	2.85e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—TGFB1—focal segmental glomerulosclerosis	1.29e-05	2.85e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.28e-05	2.85e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.27e-05	2.83e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.27e-05	2.82e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AGT—focal segmental glomerulosclerosis	1.27e-05	2.81e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TGFB1—focal segmental glomerulosclerosis	1.26e-05	2.8e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.26e-05	2.79e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGTR1—focal segmental glomerulosclerosis	1.25e-05	2.78e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.25e-05	2.78e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—SERPINE1—focal segmental glomerulosclerosis	1.25e-05	2.77e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.24e-05	2.75e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.24e-05	2.75e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.21e-05	2.69e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—GNAQ—focal segmental glomerulosclerosis	1.21e-05	2.69e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.2e-05	2.66e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.19e-05	2.65e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—LIPC—focal segmental glomerulosclerosis	1.19e-05	2.65e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.16e-05	2.58e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AGT—focal segmental glomerulosclerosis	1.15e-05	2.56e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.15e-05	2.55e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NOS2—focal segmental glomerulosclerosis	1.15e-05	2.55e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.15e-05	2.54e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AGT—focal segmental glomerulosclerosis	1.14e-05	2.52e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.13e-05	2.51e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.12e-05	2.49e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.12e-05	2.48e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—AGT—focal segmental glomerulosclerosis	1.12e-05	2.48e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.1e-05	2.45e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	1.1e-05	2.44e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—SERPINE1—focal segmental glomerulosclerosis	1.09e-05	2.42e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	1.09e-05	2.42e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.06e-05	2.36e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EDN1—focal segmental glomerulosclerosis	1.06e-05	2.35e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	1.06e-05	2.35e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CTGF—focal segmental glomerulosclerosis	1.05e-05	2.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—FN1—focal segmental glomerulosclerosis	1.05e-05	2.33e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—LPL—focal segmental glomerulosclerosis	1.03e-05	2.28e-05	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—ALB—focal segmental glomerulosclerosis	1.02e-05	2.27e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	1.02e-05	2.27e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—TGFB1—focal segmental glomerulosclerosis	1.01e-05	2.24e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AGT—focal segmental glomerulosclerosis	9.95e-06	2.21e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SPP1—focal segmental glomerulosclerosis	9.75e-06	2.16e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—ALB—focal segmental glomerulosclerosis	9.72e-06	2.16e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GNAQ—focal segmental glomerulosclerosis	9.68e-06	2.15e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—SERPINE1—focal segmental glomerulosclerosis	9.67e-06	2.15e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—LPL—focal segmental glomerulosclerosis	9.65e-06	2.14e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	9.59e-06	2.13e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—TGFB1—focal segmental glomerulosclerosis	9.54e-06	2.12e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.53e-06	2.12e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LIPC—focal segmental glomerulosclerosis	9.53e-06	2.11e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9.34e-06	2.07e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.33e-06	2.07e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FN1—focal segmental glomerulosclerosis	9.19e-06	2.04e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	9.19e-06	2.04e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—LPL—focal segmental glomerulosclerosis	9.12e-06	2.02e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	9e-06	2e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.85e-06	1.96e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ALB—focal segmental glomerulosclerosis	8.84e-06	1.96e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AGT—focal segmental glomerulosclerosis	8.81e-06	1.95e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	8.73e-06	1.94e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—TGFB1—focal segmental glomerulosclerosis	8.59e-06	1.91e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—focal segmental glomerulosclerosis	8.57e-06	1.9e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.56e-06	1.9e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CTGF—focal segmental glomerulosclerosis	8.39e-06	1.86e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—TGFB1—focal segmental glomerulosclerosis	8.28e-06	1.84e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AGT—focal segmental glomerulosclerosis	8.26e-06	1.83e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FN1—focal segmental glomerulosclerosis	8.14e-06	1.81e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	8.1e-06	1.8e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.9e-06	1.75e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—focal segmental glomerulosclerosis	7.87e-06	1.75e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AGT—focal segmental glomerulosclerosis	7.8e-06	1.73e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GNAQ—focal segmental glomerulosclerosis	7.73e-06	1.72e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	7.65e-06	1.7e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LIPC—focal segmental glomerulosclerosis	7.35e-06	1.63e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.3e-06	1.62e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—LPL—focal segmental glomerulosclerosis	7.28e-06	1.62e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.15e-06	1.59e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	7.06e-06	1.57e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	7.04e-06	1.56e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—focal segmental glomerulosclerosis	6.9e-06	1.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.78e-06	1.5e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—focal segmental glomerulosclerosis	6.77e-06	1.5e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	6.69e-06	1.48e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.68e-06	1.48e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CTGF—focal segmental glomerulosclerosis	6.47e-06	1.44e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—focal segmental glomerulosclerosis	6.34e-06	1.41e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AGT—focal segmental glomerulosclerosis	6.23e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—focal segmental glomerulosclerosis	6.1e-06	1.35e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	6.02e-06	1.34e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—focal segmental glomerulosclerosis	5.99e-06	1.33e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GNAQ—focal segmental glomerulosclerosis	5.96e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.89e-06	1.31e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.86e-06	1.3e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LPL—focal segmental glomerulosclerosis	5.81e-06	1.29e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.8e-06	1.29e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.58e-06	1.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	5.51e-06	1.22e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—focal segmental glomerulosclerosis	5.19e-06	1.15e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AGT—focal segmental glomerulosclerosis	4.97e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.83e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—focal segmental glomerulosclerosis	4.78e-06	1.06e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LPL—focal segmental glomerulosclerosis	4.49e-06	9.96e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—focal segmental glomerulosclerosis	4.27e-06	9.49e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AGT—focal segmental glomerulosclerosis	3.84e-06	8.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—focal segmental glomerulosclerosis	3.82e-06	8.47e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—focal segmental glomerulosclerosis	2.95e-06	6.54e-06	CbGpPWpGaD
